Gabelli Funds LLC Boosts Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Gabelli Funds LLC increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 13.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 147,350 shares of the medical equipment provider’s stock after buying an additional 17,000 shares during the period. Gabelli Funds LLC’s holdings in Zimmer Biomet were worth $13,323,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. DV Equities LLC purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth about $25,000. Monetary Solutions Ltd purchased a new position in Zimmer Biomet in the fourth quarter valued at about $30,000. Gen Wealth Partners Inc acquired a new stake in Zimmer Biomet during the 4th quarter valued at approximately $31,000. Flagship Harbor Advisors LLC purchased a new stake in Zimmer Biomet during the 4th quarter worth approximately $32,000. Finally, Headlands Technologies LLC purchased a new stake in Zimmer Biomet during the 2nd quarter worth approximately $37,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several recent analyst reports. Citigroup cut their price target on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Leerink Partners started coverage on shares of Zimmer Biomet in a report on Monday, April 13th. They set a “hold” rating and a $101.00 price objective for the company. Barclays cut their target price on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a research note on Wednesday, April 29th. JPMorgan Chase & Co. lowered their price objective on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. Finally, Truist Financial restated a “hold” rating and set a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $100.70.

Insider Buying and Selling

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.28% of the stock is currently owned by corporate insiders.

Zimmer Biomet Stock Performance

ZBH opened at $91.35 on Monday. The business’s 50 day moving average is $87.90 and its 200-day moving average is $89.79. The stock has a market cap of $17.67 billion, a PE ratio of 23.73, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s payout ratio is presently 24.94%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.